Is the price fair?
What MCK's price assumes
McKesson Corporation trades at 23.4× earnings against 31.5× for the median Healthcare name, cheaper than its own group.
23.4
Trailing P/E · Healthcare median 31.5 · cheaper than the typical name in its group
- Price / sales
- 0.25
Price / sales · as of 2025-Q4
- Free cash flow yield
- 6.5%
Free cash flow yield · Healthcare median 4.7%
- Growth the price implies
- +2.2%
Growth the price implies · The price pays for +2.2% free cash flow growth a year for a decade; the business has delivered +6.2% a year over the last three.
Details›
- EV / EBIToperating margin 1.5%: the multiple describes the denominator
- not meaningful
- EV / sales2025-Q4
- 0.26
- Healthcare median P/E362 names
- 31.5
- Free cash flow, trailing twelve months
- $5.72B
- Market capitalisation
- $87.9B
- 3-year revenue growth
- +13%
- 3-year free cash flow growth
- +6.2%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $628.92 |
| Its own P/E history, median | $852.50 |
| Its own P/E history, upper quartile | $990.04 |
| 52-week range | $656.34 – $994.59 |
| Today | $896.78 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Healthcare
Ranks #240 of 345 by Smart Score